Synthesis and in vitro anticancer evaluations of Deferasirox iron chelator
نویسندگان
چکیده
منابع مشابه
Deferasirox: a novel, once-daily oral iron chelator
10.1586/14750708.3.4.453 © 2 Regular blood transfusions for the treatment of chronic anemia inevitably lead to iron overload since humans do not possess a physiological mechanism for removing excess iron. Without appropriate treatment, the cumulative effects of iron overload lead to severe organ damage and, ultimately, death. The iron chelating agent, deferoxamine, has been used effectively for...
متن کاملsynthesis of sulfides from alcohols and thiols in solvent-freeconditions and deoxygenation of sulfoxides
کاتالیست یک سنتز جدید برای تیواترها توصیف شده است. واکنش الکل ها با آریل، هتروآریل و آلکیل تیو ل ها درحضور 1،3،5- تری آزو- 2،4،6- تری فسفرین-2،2،4،4،6،6 هگزاکلراید ((tapc به عنوان یک کاتالیست موُثر، بازده های خوب تا عالی از تیواترها را حاصل می کند. علاوه براین، واکنش تحت شرایط بدون فلز و بدون حلال پیش می رود، بنابراین یک مکمل جالب برای روش های شناخته شده سنتز تیواترها ارائه می دهد. یک مکانیسم ا...
15 صفحه اولThe iron chelator deferasirox protects mice from mucormycosis through iron starvation.
Mucormycosis causes mortality in at least 50% of cases despite current first-line therapies. Clinical and animal data indicate that the presence of elevated available serum iron predisposes the host to mucormycosis. Here we demonstrate that deferasirox, an iron chelator recently approved for use in humans by the US FDA, is a highly effective treatment for mucormycosis. Deferasirox effectively c...
متن کاملDeferasirox, an oral iron chelator, prevents hepatocarcinogenesis and adverse effects of sorafenib
Although sorafenib is expected to have a chemopreventive effect on hepatocellular carcinoma (HCC) recurrence, there are limitations to its use because of adverse effects, including effects on liver function. We have reported that the iron chelator, deferoxamine can prevent liver fibrosis and preneoplastic lesions. We investigated the influence of administering a new oral iron chelator, deferasi...
متن کاملEfficacy and safety of deferasirox, an oral iron chelator, in heavily iron-overloaded patients with β-thalassaemia: the ESCALATOR study
OBJECTIVE Many patients with transfusional iron overload are at risk for progressive organ dysfunction and early death and poor compliance with older chelation therapies is believed to be a major contributing factor. Phase II/III studies have shown that oral deferasirox 20-30 mg/kg/d reduces iron burden, depending on transfusional iron intake. METHODS The prospective, open-label, 1-yr ESCALAT...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of Cellular Immunotherapy
سال: 2015
ISSN: 2352-1775
DOI: 10.1016/j.jocit.2015.10.043